Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cognition Therapeutics Inc (CGTX)

Cognition Therapeutics Inc (CGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,179
  • Shares Outstanding, K 41,548
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,790 K
  • EBIT $ -58 M
  • EBITDA $ -58 M
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.76
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.97
  • Most Recent Earnings $-0.25 on 11/13/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.34
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +25.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3750 +68.03%
on 11/27/24
1.2900 -51.16%
on 12/18/24
+0.1901 (+43.20%)
since 11/20/24
3-Month
0.3400 +85.32%
on 10/11/24
1.2900 -51.16%
on 12/18/24
+0.0505 (+8.71%)
since 09/20/24
52-Week
0.3400 +85.32%
on 10/11/24
2.9500 -78.64%
on 05/23/24
-1.0399 (-62.27%)
since 12/20/23

Most Recent Stories

More News
Cognition Therapeutics Announces Promising Phase 2 Results for CT1812 in Dementia with Lewy Bodies, Plans Advancement to Late-Stage Trials

Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials.Quiver AI SummaryCognition Therapeutics, Inc. announced promising...

CGTX : 0.6301 (-0.62%)
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

CGTX : 0.6301 (-0.62%)
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

CGTX : 0.6301 (-0.62%)
Cognition Therapeutics, Inc. Reports 95% Reduction in Cognitive Decline in Alzheimer’s Patients Treated with CT1812 in Phase 2 SHINE Study

CT1812 treatment shows a 95% reduction in cognitive decline and improvement in Alzheimer’s biomarkers in Phase 2 study.Quiver AI SummaryCognition Therapeutics, Inc. announced significant findings from...

CGTX : 0.6301 (-0.62%)
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

CGTX : 0.6301 (-0.62%)
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

CGTX : 0.6301 (-0.62%)
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

CGTX : 0.6301 (-0.62%)
November’s Small-Cap Treasures: 3 Stocks Poised for Growth

Three promising small-cap stocks, poised for growth in healthcare, cybersecurity, and renewable energy, offer compelling investment opportunities for November.

LODE : 0.3371 (+11.81%)
CGTX : 0.6301 (-0.62%)
ASNS : 1.0300 (+0.98%)
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

CGTX : 0.6301 (-0.62%)
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

CGTX : 0.6301 (-0.62%)

Business Summary

Cognition Therapeutics Inc.is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics Inc.is based in PURCHASE,...

See More

Key Turning Points

3rd Resistance Point 0.7759
2nd Resistance Point 0.7267
1st Resistance Point 0.6784
Last Price 0.6301
1st Support Level 0.5809
2nd Support Level 0.5317
3rd Support Level 0.4834

See More

52-Week High 2.9500
Fibonacci 61.8% 1.9530
Fibonacci 50% 1.6450
Fibonacci 38.2% 1.3370
Last Price 0.6301
52-Week Low 0.3400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar